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Abstract
Clostridium perfringens, a rapid-growing pathogen known to secrete an arsenal of >20 virulent toxins, has been
associated with intestinal diseases in both animals and humans throughout the past century. Recent advances in
genomic analysis and experimental systems make it timely to re-visit this clinically and veterinary important pathogen.
This Review will summarise our understanding of the genomics and virulence-linked factors, including antimicrobial
potentials and secreted toxins of this gut pathogen, and then its up-to-date clinical epidemiology and biological role
in the pathogenesis of several important human and animal-associated intestinal diseases, including pre-term
necrotising enterocolitis. Finally, we highlight some of the important unresolved questions in relation to C. perfringens-
mediated infections, and implications for future research directions.
Introduction
Clostridium perfringens (formerly known as Bacillus
aerogenes capsulatus, Bacillus perfringens, Bacillus welchii
or Clostridium welchii) is a Gram positive, spore-forming,
anaerobic, rod-shaped bacterium1. It was ﬁrst isolated and
identiﬁed as a novel bacterium in 1891 by William H.
Welch from the autopsy of a 38-year-old man, where gas
bubbles were observed within infected blood vessels. This
gas-forming trait (the original name Bacillus aerogenes
capsulatus, ‘aerogenes’ literally means ‘air-producing’ in
Latin) was later linked to gas gangrene symptoms seen in
British and French soldiers during World War I2.
C. perfringens is associated with diverse environments
including soils, food, sewage, and as a member of the
gastrointestinal (GI) tract microbial community (i.e.,
microbiota) of both diseased, and non-diseased humans
and animals. Notably it has been associated with humans
for thousands of years as evidenced by the recent identi-
ﬁcation of C. perfringens using next generation sequen-
cing (NGS) technology in the mummiﬁed GI tract of a
>5000-year-old Neolithic ‘Tyrolean Iceman’ (also known
as Ötzi), found in an Alpine glacier in 19913.
Clinically, C. perfringens has been constantly associated
with various signiﬁcant systemic and enteric diseases, in
both humans and animals, including gas gangrene
(Clostridial myonecrosis), food poisoning and non-
foodborne diarrhoea, and enterocolitis4,5. Importantly,
C. perfringens strains are known to secrete >20 identiﬁed
toxins or enzymes that could potentially be the principal
virulence factors involved in pathophysiology6.
In this Review, we explore phenotypic and genomic
features of this important and re-emerging pathogen,
including virulence factors, and antimicrobial resistance
(AMR) proﬁles, and the clinical impact of this bacterium
in relation to numerous medically important intestinal
diseases, across several host species. Finally, we highlight
some of the important unresolved questions in relation to
C. perfringens-associated infections, and implications for
future research directions.
Isolation, identiﬁcation and typing methods
There are numerous methods for isolation of C. per-
fringens, and biochemical and molecular methods for
identiﬁcation as detailed in Table 1.
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As C. perfringens is a pathogen, typing methods are
currently used to differentiate between strains that may be
associated with serious infection (Table 1). C. perfringens
strains, clinically well-known for toxin production, are
typed (recently updated for seven toxinotypes: A–G;
previously only types A–E7) according to the combination
of typing toxins (Fig. 1) they produce, i.e., α-toxin, β-toxin,
ε-toxin and ι-toxin, enterotoxin (CPE) and NetB8. His-
torically this method indicated that certain toxins were
associated with certain hosts and diseases e.g., type B
(particularly the β-toxin it harbours), is exclusively linked
to dysentery in sheep, and rarely seen in other hosts9.
Food-poisoning associated CPE was genotyped typically
in type F strains (previously named as CPE-positive type
A; not to be confused with heat-resistant type C strains)
although CPE can also be produced by certain type C, D
and E strains, whereas β2-toxin and θ-toxin (per-
fringolysin O; PFO) could be found in any tox-
inotypes1,10,11. However, it is important to note that no
single strain is known to produce the entire panoply of
toxins10.
Genomic insights
C. perfringens has a relatively low GC content, between
27–28%, and genome sizes range from 3.0–4.1Mb, with
2500–3600 predicted genes present in each individual
genome10. The ﬁrst ever complete genome sequence of C.
perfringens (strain 13) was published in early 2002; a
historical gas gangrene-associated strain from 1939 (this
also represents the ﬁrst Gram-positive anaerobic patho-
gen to be sequenced)12. Virulence-linked genes within the
sequence data include phospholipase C (α-toxin), hya-
luronidase (µ-toxin), collagenase (κ-toxin), PFO (θ-toxin),
and β2 toxin. Moreover, 61 sporulation-related and
germination-related genes were encoded, which supports
the fact that C. perfringens is a spore-former. Notably,
most virulence genes in this type A strain were not found
on genomic islands, or near insertion/transposase
sequences, and GC content of those genes were similar to
the average GC percentage, implying that horizontal gene
transfer (HGT) of these toxin genes was an ancient evo-
lutionary event. This study also highlighted differences in
environmental adaption genes, including glycolytic
Table 1 Common isolation, identiﬁcation and typing methods used in C. perfringens research
Method Method details in brief Refs
Isolation
Direct plating Direct plating on TSC-EYA+ 18–24 h anaerobic incubation at 37 °C. Pitch black colonies with opaque halos
are presumptively C. perfringens.
146
Ethanol pre-treatment Ethanol pre-treatment (50% ethanol) for 30 mins+ plating on Fastidious Anaerobe Agar (sometimes
supplemented with 0.1% taurocholate). Colonies that exhibit beta-haemolysis are preliminarily identiﬁed as
C. perfringens.
147
Biochemical identiﬁcation
Nagler’s reaction Known as lecithinase (alpha-toxin) test. Egg-yolk agar plates are split into two halves, where one half
contains anti-alpha-toxin, and following anaerobic incubation, positivity is deﬁned as turbidity around
colonies on the anti-alpha-toxin-free side which conﬁrms C. perfringens.
148
Reverse CAMP test Streptococcus agalactiae is streaked on blood agar, and C. perfringens streaked perpendicular to S. agalactiae.
After 24–48 h of anaerobic incubation, a ‘bow-tie’ zone will form due to the synergistic haemolysis, this
conﬁrms C. perfringens.
149
Molecular identiﬁcation
16S ribosomal RNA PCR Appropriating full-length 16S rRNA universal primers/smaller region of 16S rRNA gene in PCR to amplify 16S
rRNA gene+ sequencing, and identify using informatics approach (based on sequence similarity >97% to
assign taxonomy).
30
MALDI-TOF Mass Spectrometry Rapid and inexpensive identiﬁcation method based upon the mass spectrum analysis of highly-conserved
ribosomal proteins from whole bacterial cells—apply bacterial colonies straight onto the MALDI-TOF metal
target and followed by appropriate treatments and analysis.
4
Typing
Multiplex PCR Multiplex PCR approach is commonly used to amplify key toxins genes to classify C. perfringens into 7 (A to
G) different toxinotypes according to the toxin genes combination.
150
Genome-wide sequence
search
Genome-wide search on relevant toxin genes using sequence similarity search program e.g. BLAST for
toxinotyping on C. perfringens genomes.
10
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enzymes, and sporulation-linked genes, whereas recent
studies indicated that phylogenetic relationships between
C. perfringens (based on core genome analysis) does not
relate to clone origin or toxinotypes1,10
A recent large-scale genomic study that investigated
56 strains C. perfringens strains, representing the largest
C. perfringens genomic study to date, revealed a diverse
pangenome (a repertoire of genes in a deﬁned number of
genomes), with only 12.6% core genes (common genes
that are present in each genome) (Fig. 2)10. A wide array
of toxin genes was proﬁled in this study: α-toxin (plc), α-
clostripain (ccp) and microbial collagenase (colA) were
conserved in all examined genomes, the pore-forming
toxin PFO gene pfo was found to be encoded in most
genomes (>90%), whereas the food-poisoning causative
toxin CPE gene cpe was consistently detected in historical
food poisoning isolates (isolated before 1950s). Impor-
tantly, prevalence of aminoglycoside-resistant/anti-
defensin gene mprF (100% detection), and tetracycline-
resistant efﬂux protein genes tetA (P) (>75% detection)
encoded within the genomes underlined the potential
antimicrobial resistant threat of C. perfringens-associated
infection. This study also suggested that these diverse
genetic variations may have been driven by HGT, espe-
cially prophage insertion, within the ‘CRISPR-free’ gen-
omes (no single CRISPR prophage defence system
detected in >70% of the genomes).
The substantial genetic divergence in the C. perfringens
pangenome suggests there may be additional novel
virulence-related genes encoded within the ‘accessory
genome’, in addition to the plasmid-borne toxins, known
to be primarily responsible for speciﬁc disease patholo-
gies. Thus, it is important to analyse plasmid-encoded
genes/toxins, in tandem to chromosomally-encoded genes
in the accessory genome, to provide a more complete
genomic picture of C. perfringens. Potentially, with the aid
of bioinformatics tools, more novel toxins or virulence
genes will be discovered and identiﬁed for investigation in
relation to C. perfringens pathogenicity, and disease
transmission tracking in hospital and environmental set-
tings, as has been performed for the related gut pathogen
C. difﬁcile13. To fully determine and research the pan-
genome, and discover potentially novel virulence genes,
more isolate sequencing will be required, including
addition of isolates from a range of hosts and environ-
mental conditions, which may pave the way for transla-
tional research into new treatment strategies against C.
perfringens infections.
Fig. 1 C. perfringens current toxinotyping system. The names of
toxin genes are printed in grey
Box 1
Glossary
● 16S rRNA gene: a housekeeping gene (of ribosomes) that is
conserved across all species therefore is widely used as a
chronological/biological identity marker in evolutionary
genetics and genomics.
● Accessory gene: a gene that is absent in one or more strains in
an analysed pangenome.
● Antimicrobial resistance: a biological characteristic that enable
a microorganism to survive and thrive in the presence of
antibiotics.
● Core gene: a gene that is present in all strains in an analysed
pangenome.
● Genotyping: a process to differentiate/identify characteristics of
genes (genotypes).
● Germination: the process which microorganisms grow from a
dormant state (usually from endospores).
● Necrotising Enterocolitis: severe gut inﬂammation (often
accompanied by necrosis of the gut) which occurs mostly in
pre-term infants with high mortality.
● Pangenome: The repertoire of collective genes in closely
related organisms.
● Phenotyping: a process to observe the expression/traits
(phenotypes) of an organism’s genotype.
● Sporulation: a process certain species/genus of bacteria (e.g.,
Firmicutes) undergo to produce a tough external structure
(spore/endospore) to withstand unfavourable conditions in
order to survive through.
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Plasmids
Importantly, C. perfringens strains are known to carry
plasmids, which often encode virulence-associated pro-
teins including toxins and antimicrobials14. Disease-
associated toxins including; CPE, ε-toxin, ι-toxin, NetB,
β2-toxin and binary enterotoxin (BEC) have all been
detected on C. perfringens plasmids10,15. HGT of plasmids
between strains is reported to be via the tcp conjugation
locus that exists in most plasmids16. Important toxin-
carrying plasmids will be brieﬂy reviewed in order of
toxinotypes. For comprehensive reviews on C. perfringens
plasmids, and other related insertion sequences see14,15.
CPE is known to be involved in food poisoning and
non-foodborne gastroenteritis. It was reported that up to
70% of food poisoning cases, causative C. perfringens
strains (mainly type F, previously known as CPE-positive
type A) were shown to encode chromosomal-cpe, rather
than plasmid-cpe, while the latter was associated with
non-foodborne gastroenteritis (responsible for 5–15% of
all cases)17. Some cpe-associated plasmids have also been
shown to encode cpb2 genes or iab/ibp genes (e.g.,
pCPF5603)14. Type B strains carry plasmids which encode
one of the deadliest toxins on earth, ε-toxin, and β-toxin.
Plasmid pCP8533etx encodes etx and cpb2 genes, but not
cpb18. Most plasmids in type B strains also possess other
virulence genes encoding λ-toxin and urease19. Similarly,
plasmids in type D strains also carry cpe and/or cpb2
genes, and plasmids range in size from 45 to 110 kb20. C.
perfringens type C strains possess plasmid-borne β-toxin
gene cpb, and other plasmids reported to carry other toxin
genes including cpb2, tpeL, or cpe21. In type E strains, two
major families of plasmids have been identiﬁed: (1) plas-
mids carry iap/ibp genes, λ-toxin gene and cpe gene,
however, cpe contains nonsense and missense mutations
in the cpe ORF and is thus non-functional22. (2) These
plasmids, including pCPPB-1, encode both iap/ibp genes
and cpe gene but not the λ-toxin gene23. NetB is a chicken
NE-associated toxin, which is plasmid encoded. These
Fig. 2 The linearised pangenome of 56 C. perfringens strains reveals signiﬁcant genetic diversity. Each coloured block represents synteny
(homolog: identical gene with >95% sequence similarity) in the pangenome. Figure adapted from Kiu et al.10
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netB-encoded plasmids can potentially carry other viru-
lence genes including tetracycline resistance genes (e.g.,
pJIR3537 and pCW3) and cpb2 gene (e.g., pJIR3844)24.
Notably, many toxin plasmids of C. perfringens are
highly similar, sharing up to 35–40 kb of identical
sequences15. In addition, some C. perfringens isolates can
carry multiple near-identical plasmids that encode dif-
ferent toxin and AMR genes24. However, no one isolate
has ever been found to possess plasmids that encode all
key toxins; only certain plasmid combination could can be
maintained, which suggests plasmid incompatibilities, due
to presence of distinct plasmid segregation systems, and
warrants further research14,25,26. Furthermore, the uni-
versal existence of tcp locus indicates that conjugative
plasmid transfer could be a key HGT event for increasing
virulence of C. perfringens strains.
Virulence-related factors
C. perfringens can generate a complement of extra-
cellular toxins and hydrolytic enzymes (>20), survive in
aerobic environments (i.e., oxygen tolerance), produce
toxic gases, and rapidly grow. Therefore, it possesses the
capacity to effect various histotoxic (i.e., toxigenic to tis-
sues) infections in humans, including gas gangrene in
contaminated wounds, gastroenteritis (including food-
borne and non-foodborne diarrhoea) in human adults,
necrotic enteritis (NE) in animals, and recent links to
NEC in pre-term infants27. Relevant virulence factors of
C. perfringens are represented and summarised in Fig. 3.
Transmission and colonisation
Oxygen sensitivity
C. perfringens is commonly known as a strict anaerobe;
however, this bacterium can also survive in the presence
of oxygen, and/or low concentrations of superoxide or
hydroxyl-radical-generating compounds28. Notably, as an
aero-tolerant anaerobe, C. perfringens could potentially
survive through aerobic environments (such as on sur-
faces in hospital wards29) and trigger disease development
in aerophillic environments (i.e., adult/pre-term infant
gut), and additionally oxygen-exposed tissues (such as gas
gangrene), which may facilitate bacterial host-to-host
transmission30.
Sporulation
C. perfringens is a spore-former, which enables this
bacterium to survive in extreme or nutrient-depleted
conditions. This spore-forming characteristic plays a vital
role in the transmission of this Gram-positive bacterium
from diverse environments to hosts, leading to infection,
including food poisoning in human adults31. Some spores
of C. perfringens (especially food-poisoning associated
strains) had been demonstrated to resist extreme tem-
perature conditions, which may contribute to C.
perfringens survival and subsequent disease pathology32,33.
Molecular regulation of sporulation in C. perfringens is
less well studied compared to the model bacterium
Bacillus subtilis. Previous studies have indicated that the
transcriptional regulator CcpA (encoded by ccpA) is
required for effectual sporulation34 and Spo0A (spo0A), a
transcriptional factor known to be present in Clostridium
species including C. perfringens, is associated with spor-
ulation initiation35. Sigma factors, including SigF, SigE,
SigG and SigK (genes sigF, sigE, sigG and sigK respec-
tively) are known to regulate the sporulation process of
C. perfringens36,37. In addition to this, it was also reported
that C. perfringens sporulation processes could be
regulated by an Agr-like quorum-sensing system, poten-
tially promoted by the codY gene in type A food-
poisoning strains38,39. Importantly, CPE is known to be
produced by C. perfringens during sporulation, which
correlates with the pathogenesis of food poisoning-
associated diarrhoea31.
Germination
Germination of C. perfringens can be triggered by small
molecules termed germinants—commonly known as
sugars, nucleosides, amino acids, salts and purines40.
Importantly, primary bile acids (including glycocholate,
cholate and taurocholate) in the human GI tract are also
known to act as potent germinants in Clostridium species,
whereas secondary bile acids, such as deoxycholate
(derivatives generated by certain gut microbes), can
inhibit the in vitro proliferation of C. perfringens41. This
proposed ‘colonising germination’ survival modus oper-
andi of spore-formers, including C. perfringens, potentially
acts as a signal to initiate growth, and to persist in the
intestinal environment30. This persistence, and long-term
gut colonisation may correlate with the ongoing symp-
toms (up to several weeks) of nonfoodborne diarrhoea in
patients42. From a colonisation resistance perspective,
inhibition of germination, by secondary bile products
produced by resident commensal bacteria, implies a long-
standing competition for limited nutrients and niches
within the gut.
Rapid proliferation
Notably, C. perfringens represents one of the fastest-
growing organisms currently known, and is reported to
have a very short 8–12 min generation time when cul-
tured at 43 °C in optimal media, and 12–17min at 37 °C43.
Rapid growth of this bacterium potentially predisposes
the host to tissue infection, as in the cases of avian NE,
bovine necro-haemorrhagic enteritis (could be <5 h), and
gas gangrene. Also, as C. perfringens has a two-fold
quicker generation time, when compared to intestinal
commensals like wild-type Escherichia coli (typically
20–30 min in Luria-Bertani broth), this could represent a
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potent mechanism for outgrowing other resident bacteria,
leading to efﬁcient gut colonisation.
Disease initiations
Histotoxic gas production
Clostridial myonecrosis (better known as gas gangrene),
is accompanied by profuse gas production, which could in
theory be the mechanical determinant of tissue injury,
alongside rapid cell proliferation of C. perfringens.
Importantly, C. perfringens is known to generate hydrogen
sulphide44 (using ubiquitous sulphuric sources from the
environment), a readily-permeable toxic substance to
human cells, which when produced in excess is associated
with other intestinal inﬂammatory diseases (e.g., Ulcera-
tive Colitis)45. Thus, C. perfringens-associated gas pro-
duction represents an understudied virulence trait in the
pathogenesis of gut infection, such as infant NEC (dis-
cussed in more detail below), which symptoms sig-
niﬁcantly mimic those of gas gangrene; necrosis of tissue
accompanied by abundant gas production46,47.
Toxins and virulent enzymes
Presently, 23 virulence genes that encode toxins and
virulent enzymes have been identiﬁed in C. perfringens
Fig. 3 Graphical representation of disease-linked virulence factors of C. perfringens in the context of intestinal infections. Classiﬁcation of
toxins according to general mechanisms of action are shown in the bottom blue box
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(summarised in Table S1); the most ‘proliﬁc’ toxin-
producing pathogen currently known. Some key toxins
will be brieﬂy discussed and summarised in this sub-
section.
Alpha-toxin
Alpha-toxin (encoded by gene plc or cpa), which is
produced by all strains of C. perfringens, has been shown
to hydrolyse cell membrane phospholipids, which even-
tually leads to cell necrosis; a key characteristic in gas
gangrene. Indeed, this toxin is essential for gas gangrene
pathology, as shown in an in vivo myonecrosis model48.
Mechanistically, α-toxin may play three major roles in gas
gangrene pathology; ﬁrstly, it is able to impact the
transferring of immune cells such as neutrophils to
infected tissues (mechanism currently unknown), hence
potentially reducing pathogen clearance at infected sites.
Secondly, it can cause constriction of blood vessels, which
may reduce the blood supply to tissues, thus creating a
micro-aerophillic environment conducive to C. perfrin-
gens overgrowth. Thirdly, this toxin can activate inﬂam-
mation cascades in host cell metabolism (arachidonic acid
and protein kinase C), which may lead to direct immune-
mediated pathology of tissues49.
Beta-toxin
Beta-toxin, encoded by gene cpb, is a plasmid-encoded
pore-forming toxin that is thought to be intestinal-
necrotic, and also important for systemic enterotoxaemia,
in humans and neonatal animals, as shown in in vivo
studies50,51. C. perfringens type C strains that possess the
cpb gene were associated with historical Clostridial gut
infections; Darmbrand (post-world war II in Germany),
and Pig Bel (Papua New Guinea)52. Previous intestinal
loop studies have indicated a synergistic effect with CPE
(encoded by cpe)53. Furthermore, this toxin shares
sequence similarity with several pore-forming toxins
produced by Staphylococcus aureus – ɣ toxin (A: 22 and
B:28%), α-toxin (28%) and leucocidin (S:17% and F:28%)54.
Perfringolysin O
PFO (also θ-toxin, encoded by gene pfoA or pfo), is also
a pore-forming toxin that acts on cholesterol-comprising
cell membranes. This toxin has been shown to be involved
in the pathogenesis of gas gangrene, and haemorrhagic
enteritis in calves55,56. Notably, PFO shares structural
homology with similar pore-forming toxins identiﬁed in
Streptococcus, Bacillus, Listeria and many other genera57.
θ-toxin is also known for its capacity to induce tumour
necrosis factor alpha (TNF-α) and interleukin 6 (IL-6)
expression in the host, and it could activate apoptosis
through p38 MAPK (mitogen-activated protein kinase)
pathway as demonstrated in in vitro models58. Interest-
ingly, it has synergistic cytotoxic effects with α-toxin on
bovine epithelial cells, highlighting the signiﬁcant role of
this toxin in disease development56,59.
Beta2-toxin
Beta2-toxin (encoded by cpb2 plasmid gene), a pore-
forming cytolytic toxin shares <15% sequence homology
with β-toxin, distinguished itself as a novel toxin pro-
duced by C. perfringens54. β2-toxin-producing C. per-
fringens strains have been associated with gut diseases
such as NE in piglets, and enterocolitis in foals60.
Importantly, this pore-forming toxin has been suggested
as an accessory toxin in C. perfringens-associated non-
foodborne diarrhoea61, and proposed to play an important
role in pre-term NEC in potential synergistic effects with
antibiotic gentamicin62.
Epsilon-toxin
This deadly toxin, is plasmid-encoded by etx gene C.
perfringens type B and D strains, and is essential for
pathogenesis. Epsilon toxin is involved in animal (goat
and sheep) enterotoxaemia63. ε-toxin is currently thought
to be the most potent of all toxins produced by C. per-
fringens, evidenced by the LD50 of 70 ng/kg body weight,
ranked only behind C. botulinum and C. tetani neuro-
toxins. It has been demonstrated to affect various organs,
such as kidneys and liver, through unknown mechanisms,
that allow this toxin to enter systemic circulation64. Due
to its potential use as a biological weapon, ε-toxin-
producing C. perfringens strains are on the export control
list in a number of countries including USA and the UK.
Iota-toxin
This cytoskeleton-damaging toxin (also considered as a
major toxin produced by C. perfringens), consists of two
cell-binding monomers Ia (enzymatic component) and Ib
(binding component; encoded on plasmids by iap and ibp
gene respectively), which act synergistically to ﬁrst
translocate the toxin into host cells, then exert enzymatic
activity on ADP-ribosylating actin to disassemble the
cytoskeleton, which eventually leads to apoptosis and cell
death65.
Microbial collagenase
Microbial collagenase (also known as κ-toxin), encoded
by chromosomal gene colA, is a key toxin produced by C.
perfringens that degrades collagen. This enzyme might
contribute to intestinal infection, as collagen, the sub-
strate for collagenase, is a primary component of intest-
inal connective tissues/basal membrane of human and
animal hosts, thus disruption may damage basal integrity,
which may lead to eventual tissue necrosis56,66. However,
Awad et al.67 indicated that κ-toxin is not a major
determinant in a Clostridial myonecrosis mouse model
(gas gangrene), despite its capacity to hydrolyse collagen.
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Enterotoxin (CPE)
CPE (encoding gene cpe) is recognised as the key toxin
to cause food-poisoning and non-foodborne diarrhoea, it
has also been demonstrated to disrupt the intercellular
claudin tight junctions in gut epithelial cells68,69. Impor-
tantly, this pore-forming toxin was demonstrated to bind
and necrotise human ileal and colonic epithelium in vitro,
and can induce cell death i.e., apoptosis, via the caspase-3
pathway70. Hence, the potential pathogenesis mechanisms
underlying food poisoning could result from CPE-induced
tight junction rearrangements or pore-formation.
Sialidase
Three sialidases, encoded by genes nanH, nanI and nanJ
in C. perfringens, are also named as neuraminidases or
exo-sialidases (NanI and NanJ). This group of enzymes
represent important virulence factors during C. perfrin-
gens-mediated tissue infection; they catalyse hydrolysis of
terminal sialic acids from glycoprotein, glycolipids and
polysaccharides of cell membranes that aids in bacterial
attachment to host cells71. This mucolytic potential sug-
gests that C. perfringens may utilise intestinal mucus as a
nutrient source, and thereby potentiates intestinal colo-
nisation, which has been modelled using the in vitro
Caco-2 cell line72. Importantly, in vitro studies have also
demonstrated that α-toxin associated with NanI (exo-
alpha-sialidase) increased the virulence of C. perfringens73.
Furthermore, NanI was shown to potentiate the virulence
of ε-toxin, β-toxin and CPE, via binding-enhancing (ε-
toxin) and proteolytic activation (β-toxin and CPE)
mechanisms, potentially enhancing C. perfringens patho-
genesis74. Notably, in a gas gangrene mouse model, NanI
and NanJ are not essential for virulence75.
NetB
NetB, a pore-forming toxin (encoded by netB), shares
limited amino acid sequence similarity with beta-toxin
(38% sequence identity), α-toxin from S. aureus (31%
sequence identity) and δ-toxin (40% sequence identity)
from C. perfringens76. Less than a decade ago, this
chicken-NE associated toxin (plasmid-borne), was dis-
covered and shown to be essential (instead of α-toxin) for
lesion formation both in cell line models, and avian in vivo
models via genetic mutant strains, and thus fulﬁlled
molecular Koch’s postulates as a disease determinant77.
This toxin is important in avian agriculture as netB-
positive C. perfringens strains recovered from broiler
chickens (healthy birds) can be as high as 61%, however
expression of NetB was shown to be lower in healthy
birds, when compared with NE-associated chickens (92%
vs. 29%)78. In addition, netB was later identiﬁed as part of
a plasmid-encoded pathogenicity locus named NELoc-1
capable of being transferred via conjugation, indicating
the potential spread in relation to chicken NE
epidemiology24,79. Please refer to Review by Rood et al.80
for a comprehensive description on NetB and poultry NE.
These extracellular toxins represent potent virulence
factors central to intestinal disease development. How-
ever, not all toxins are secreted by all strains of C. per-
fringens (excluding α-toxin), hence, in silico identiﬁcation
of virulence genes using NGS techniques and bioinfor-
matics tools are essential for rapid and comprehensive
geno-toxinotyping of C. perfringens, compared with con-
ventional molecular tools.
Antimicrobial resistance (AMR)
AMR traits in C. perfringens pose a serious clinical
treatment concern, due to its capacity to generate an array
of lethal toxins. Presently there are several phenotyping
studies published (based on in vitro susceptibility testing
of minimal inhibitory concentration; MIC, Table S2) on
the AMR proﬁle of C. perfringens, however, there is cur-
rently limited genetic/WGS-based AMR genotyping
studies.
Tetracycline resistance in C. perfringens was ﬁrst
described in 1968, when 11 strains of C. perfringens were
tested, and found to possess ‘some degree’ of resistance to
tetracycline, thus penicillin G (or, benzylpenicillin) was
recommended as the drug of choice for treating Clos-
tridial infection81. Plasmid-carrying tetracycline resistance
(tet components) in C. perfringens was genetically shown
for the ﬁrst time in porcine samples (three strains)82.
Tetracycline resistance elements tetA(P), was then
detected in 81 tetracycline-resistance C. perfringens
strains (100%), with 93% of these strains carrying a sec-
ondary resistance gene, either tetB(P) or tet(M), notably,
no single strain possesses all tet genes83. Multidrug-
resistant C. perfringens strains were ﬁrst reported back in
1977, multiple strains (n= 7) isolated from porcine faeces
were demonstrated to be resistant against tetracycline
(MIC > 32 μg/ml), erythromycin (MIC > 128 μg/ml), clin-
damycin (MIC > 64 μg/ml), and lincomycin (MIC > 128
μg/ml)84. A PCR-based AMR study on 160 environmental
strains (water, soil and sewage) revealed encoded mac-
rolide resistance genes erm(B)(26%), erm(Q)(1%), and mef
(A)(18%), in addition to the commonly found tetA(P)
(53%), tetB(P)(22%), and tet(M)(8%)85.
Macrolide and Lincosamide resistance (mainly ery-
thromycin and lincomycin) appears widespread86, and
therefore is considered ineffective in treating C. perfrin-
gens infections. This is supported by a recent multidrug-
resistance study of 260 strains of C. perfringens isolated
from diarrheal neonatal piglets in Thailand, where higher
resistance was observed for erythromycin, lincomycin and
tylosin87.
Recent WGS studies on AMR genes have detected
mepA (multidrug-resistance gene), using various public
AMR databases on C. perfringens strains88, and also
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tetracycline resistant genes tetA(P), tetB(P) and tet38. The
genes, mprF and rpoB (rifampin-resistant) have also been
reported to be encoded88. Anti-defensin gene mprF (pos-
sibly involved in multidrug-resistant, including resistance
against gentamicin) was recently reported in a large-scale
genomic study of C. perfringens (n= 56 strains) to be pre-
sent in 100% of the genomes10. In this latest genomic study,
tetA(P) was detected in 75% of the 56 strains, which is more
prevalent than tetB(P)(42%). Interestingly, ANT(6)-Ib, an
aminoglycoside resistance gene, was also reported to be
encoded in a C. perfringens toxinotype C strain. Although
mainly anaerobic bacteria like C. perfringens may have
reduced transport of aminoglycosides intracellularly, there
are also ﬁndings that C. perfringens are sensitive to ami-
noglycosides like Gentamicin at higher concentration,
which indicates that C. perfringensmight also have acquired
additional resistance to aminoglycosides89,90.
WGS will be a key tool in the ﬁght against C. perfringens
AMR, particularly in rapid diagnostics, however gold-
standard phenotypic MIC tests will also be required to
clinically determine the antimicrobial susceptibilities, and
facilitate antibiotic management.
Clinical associations in humans and animals
C. perfringens has been constantly associated with gut
diseases across both animal and human hosts (sum-
marised in Table S3) as described in this section.
Animal hosts
Poultry NE
Poultry NE was ﬁrst documented in England in 196191.
Since then, NE has been consistently reported in every
continent around the globe. Importantly, C. perfringens is
unequivocally identiﬁed as the key aetiological organism of
NE in broiler chickens92. Global ﬁnancial impact of NE is
signiﬁcant, with an estimated economic loss of 6 billion US
$ in 2015, projecting proﬁt loss per bird at >US$0.06293.
Classic NE pathologies are characterised by gaseous
lesions and mucosa necrosis in gas-ﬁlled distended small
intestine, however, these can also involve kidney and liver
as secondary infection sites94. Proposed key biological
factors that contribute to NE are hydrolytic enzymes (e.g.,
collagenase)95, toxin production (traditionally understood
as α-toxin, and more recently NetB and TpeL, both are
pore-forming toxins, were linked to the onset of NE96.
Other NE-predisposing factors include: a high-protein
diet that favours the growth of C. perfringens, and envir-
onmental stress (e.g., high stocking density), which alters
gut microbiota/host immunity that eventually increases
risk of infection97.
Equine acute necrotising enterocolitis
Acute necrotising enterocolitis (ANEC) in foals/horses
(caused by C. perfringens) is a severe intestinal disease that
resembles the classic clinical signs of C. perfringens-
infections; rapid disease development and necrotic
intestines (mainly the colon)98. ANEC symptoms are
characterised by bloody diarrhoea, followed by a hae-
morrhagic and necrotic gut99. Type F C. perfringens
strains (previously type A) harbouring both CPE and β2-
toxin are often associated with this deadly condition98.
More recently, NetE, NetF and NetG toxins (pore-form-
ing toxins) were proposed to underlie the pathogenesis of
foal NEC100.
Swine enterocolitis
C. perfringens type A strains (also less frequently, CPE-
harbouring type F strains) are widely considered as the
invasive agent of non-haemorrhagic EC in piglets, although
the actual pathogenesis remains undeﬁned. Similar to other
C. perfringens-intestinal infection, this disease commonly
affects one-week-old piglets, suspected to inherit (i.e., via
vertical transmission during birth) the bacterium from the
microbiota of mother sows101. Symptoms involve severe
diarrhoea (non-haemorrhagic), accompanied by necrotic
mucosa and atrophy of intestinal villi. β2-toxin was initially
believed to drive the development of this disease (backed by
epidemiological studies in 1990s), and as such was used as a
diagnostic biomarker, although this has become con-
troversial in recent years60. Type C strains that carry β-toxin
are associated with haemorrhagic EC in piglets and largely
affect 1 to 4 days old neonates101. In contrast to type
A-infection (to a lesser degree, type F-infection), type
C-infection is characterised by haemorrhagic NE, which is
proposed to be driven by the presence of type C strains and
low trypsin secretion (trypsin can inactivate β-toxin) in the
immature host gut102.
Human hosts
Darmbrand
Darmbrand, which literally means ‘burning (ﬁre)
bowels’ in German, was used to describe a particular type
of necrotic inﬂammatory gut disease (also known as
enteritis necroticans, EN) associated with C. perfringens,
that occurred epidemically post-second World War
(1944–1949) in north-west Germany103. Darmbrand
causative strains were later classiﬁed as type C strains that
carry β-toxin, and these strains are highly resistant to
heat104. Many of these type C strains also harbour CPE,
which has been shown to act synergistically with β-toxin
in an intestinal loop model and therefore CPE was sug-
gested to play a role in some cases of EN53. Notably, the
heat-resistance of this strain might be attributed to the
production of a small acid-soluble protein (Ssp4) that
could potentially play a central role in dissemination of C.
perfringens strains33. Darmbrand was believed to be
facilitated by poor post-war sanitary (bacterial con-
tamination), and malnutrition (protein-malnourished)
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conditions, as this disease disappeared within a few years
after its ﬁrst recognition.
Pigbel
Enteritis necroticans (EN), or commonly known as pig-
bel in the highlands of Papua New Guinea (PNG), is a
form of inﬂammatory gut disease that was associated with
pork-feasting activities that took place among PNG
Highlanders in outbreaks ﬁrst documented back in
1966105. The classical description of the symptoms is
‘spontaneous gangrene of small intestine, without obvious
vascular or mechanical cause’ which resembles Darm-
brand, and occurred particularly in children106. The
aetiology of this fatal infection was thought to be large co-
consumption of C. perfringens type C-contaminated pork
(due to poor hygiene), and large amount of sweet potatoes
which contain trypsin inhibitor (trypsin secreted in the
gut could break down β-toxin secreted by C. perfrin-
gens)107. Similar cases of EN were also reported in
Uganda108 and Indonesia109. Notably, EN-like cases were
also reported (rare cases) in developed countries, includ-
ing USA, in exclusively diabetic subjects, who also have
attenuated trypsin production110.
Acute watery diarrhoea (food poisoning)
C. perfringens has been associated with food poisoning
since it was ﬁrst documented in both the UK and the USA
in the 1940s111. C. perfringens-type A food poisoning, is
ranked the second most prevalent bacterial food poison-
ing in the US, estimated at 1 million cases per annum,
after Salmonella112. In the European Union (EU) member
countries, C. perfringens-linked food-poisoning outbreaks
were projected at approximately 5 million cases per year
(2011)113. C. perfringens has also been reported to affect
elderly communities, especially in care homes (North East
of England, 2012–2014; 83% of the outbreaks reported
from care homes)114. C. perfringens-linked foodborne
cases are suggested to be under-reported due to its self-
limiting symptoms, thus the statistics published based on
laboratory-conﬁrmed cases may be lower than the actual
numbers, suggesting a higher actual epidemiological
impact.
Hallmark symptoms (self-limiting, lasting 12–24 h;
mortality is uncommon) include, rapid appearance within
8–14 h after food ingestion, intestinal cramp, watery
diarrhoea without fever or vomiting115. Currently, food
poisoning C. perfringens cases are thought to be caused by
CPE (encoded by cpe gene). This secreted pore-forming
toxin is also demonstrated to disrupt intestinal tight
junction barriers and initiate disease development68.
Non-foodborne diarrhoea
C. perfringens has also been associated with non-
foodborne diarrhoea (a distinct disease entity from food
poisoning, characterised primarily by more severe symp-
toms and longer duration), which includes antibiotic-
associated diarrhoea (AAD), and sporadic diarrhoea
(SD)116,117. AAD typically occurs in 5–25% of patients after
administration of broad-spectrum antibiotics118. Non-
foodborne diarrhoea typically affects older adults that are
>60 years of age (although SD is also associated with
younger age groups)119. Clinical symptoms are abdominal
pain, prolonged diarrhoea (>3 days to several weeks), and
bloody stools120,121. Patients suffering from non-foodborne
diarrhoea, particularly AAD, can become seriously ill due to
diarrhoea-induced dehydration, and may progress to
develop colitis, although full recovery is common122.
Although other pathogenic bacteria including C. difﬁcile
(most common AAD pathogen; ~25% of cases123) and S.
aureus have also been implicated in AAD, enterotoxigenic
C. perfringens type F strains (producing CPE) are esti-
mated to be responsible for up to 15% of all AAD
cases116,124,125. CPE, produced by C. perfringens type F
strains (encoded by plasmid-borne cpe gene), has been
reported to be the aetiological agent for C. perfringens-
associated non-foodborne diarrhoea, as evidenced by the
high prevalence in diarrhoea patients, but not healthy
individuals. Importantly, type F strains have also been
linked to SD, although to a lesser extent116. AAD-
associated C. perfringens strains are also described to be
more adherent to Caco-2 intestinal cells, when compared
to other food-poisoning strains, which is attributed to the
production of sialidase NanI126. The spore-forming nat-
ure of C. perfringens could also potentially contribute to
the commonly observed disease persistence and
relapse127. Molecular detection of faecal CPE or PCR
conﬁrmation of cpe gene represents the current clinical
diagnostic method for C. perfringens-AAD128,129.
Pre-term infant NEC
Pre-term infant NEC has been clinically linked with C.
perfringens since the 1970s, as type A-C. perfringens were
isolated from necrotic tissues in many NEC cases. Nota-
bly, it was even called ‘gas gangrene of the bowel’ owing to
its reﬂection of the highly similar diseased histology with
the infamous tissue myonecrosis47.
NEC has ~14% prevalence in pre-term infants less than
1000 g birth weight (i.e., extremely low birth weight,
ELBW), a high mortality of 30% with surgical NEC, and
mortality up to 50%. NEC-related deaths account for 10%
of all mortality causes in neonatal intensive care units
(NICUs) according to a UK-nationwide study130, and is
the most severe and lethal neonatal GI emergency
worldwide131. The additional annual cost for treating
NEC in pre-term infants is conservatively estimated at
£13.5 million in the UK (excluding long-term post-sur-
gical treatment), whilst in the US $1 billion is estimated to
be spent annually by neonatal departments on NEC132.
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The involvement of bacteria in the pathogenesis of NEC
has been strongly implicated since the disease was ﬁrst
described133. Both Klebsiella spp., and C. perfringens, have
been linked to clinical NEC in recent years4. Importantly,
C. perfringens was isolated from most neonates (70%), as
early as the ﬁfth day of life, which supports the theory of
pathogen colonisation that then leads to microbial inva-
sion. Classic NEC symptoms such as pneumatosis intes-
tinalis, suggests gas-producing Gram-positive bacteria
including Clostridium spp. (also implicated consistently in
recent metagenomics studies), as the key causative
agent134,135. Most recently, the emergence of two exten-
sive pre-term infant NEC cohort studies that proﬁled
metagenomic faecal samples, have both indicated that C.
perfringens is signiﬁcantly abundant in the infant gut
microbiota prior to NEC development4,5. These studies
are supported by the substantial number of NEC studies
(14 studies to date since 1970s, more than any individual
bacterial agents, as summarised in Table S4) that have
reported C. perfringens as a potential pathogenic agent, in
addition to its established pathogenesis in many other
neonatal animal gut diseases, and further supported by
in vivo studies136. Thus, C. perfringens appears to be a
pathogenic agent of microbial-NEC, i.e., C. perfringens-
associated NEC, and may link to speciﬁc disease
symptoms137.
Being universal and resilient in habitable niches, spore
former C. perfringens may readily pass on to in-hospital
neonates through either environmental or oral transmis-
sion, and then initiate diseases in the intestine138. Pro-
posed underlying mechanisms for C. perfringens-
associated NEC include reduced bowel peristalsis in
pre-term infants (increased pathogen retention time),
universal administration of broad-spectrum antibiotics139
(that leads to reduced microbiota diversity, and the
potential rapid overgrowth of resistant spores), reduced
gut barrier integrity (non-existent mucus layer), lack of
protective bacteria4,5,131 (including Biﬁdobacterium spe-
cies, which may antagonise the growth of C. perfringens),
and immature/underdeveloped immune system that is
ineffective at ﬁghting off pathogenic bacteria46 (Fig. 4).
Bile salt factors may also be linked to disease onset.
Reduced diversity of the microbiota in pre-term infants,
including bacteria that can de-conjugate bile salts to
secondary bile acids, may allow germination of C. per-
fringens, which has also been directly indicated in the
pathogenesis of the well-studied C. difﬁcile colitis (both
species form spores and secrete colitis-related toxins)140.
To date, no particular toxin(s) has been speciﬁcally
linked with pre-term NEC, although β2-toxin has been
suggested4. Notably, C. perfringens can also be part of a
‘healthy’ human microbiota (as low as 3.5% in pre-term
neonates, nevertheless this is controversial141), thus sug-
gesting other factors play a role. Antibiotic administration
in pre-term babies is very high, with up to 97% of pre-
term infants residing in NICU exposed to at least one
dosage of broad-spectrum antibiotics142. These antibiotics
eliminate ‘protective’ members of the gut microbiota, and
in tandem with presence of AMR-C. perfringens, may
facilitate successful colonisation and infection143. An
immature gut barrier in neonatal infants may also expose
gut niches for overgrowth, and ﬁnally the presence of
‘hyper-virulent’ strains of C. perfringens may be impli-
cated. However, to comprehensibly answer these impor-
tant questions a more global genomic approach, i.e., WGS
Fig. 4 Proposed infection mechanisms that underlie C.
perfringens-associated NEC. a In non-NEC ‘healthy’ term infant gut.
b In pre-term infant gut that leads to C. perfringens-associated NEC
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and analysis, and validation using suitable in vivo models
is required.
Advancement of WGS and genomic analyses, particu-
larly those focussing on other gut pathogens including C.
difﬁcile, K. pneumoniae and Salmonella enterica has
proved successful in understanding the pathogenic role of
these bacteria in disease development and tracking bac-
terial transmission144,145. These enteric pathogens have all
been sequenced extensively with genomic information
made public on NCBI database (as of May 2018; bracke-
ted digits indicate number of genomes): C. difﬁcile (1322),
E. coli (10541), C. botulinum (225), K. pneumoniae (3927)
and S. enterica (8780). Yet, including a batch addition of
30 genomes towards the end of 2016, there are only 59
publicly available genomes of C. perfringens (May 2018),
highlighting the lack of in-depth understanding of this
pathogen with respect to its genomic information.
Importantly, no NEC-associated pre-term infant isolates
are known to be sequenced at present, and genomic
investigation may allow identiﬁcation of putative/novel
NEC-associated virulence factors, that may facilitate
intervention strategies and/or therapy development.
Future research directions
The clinical link between intestinal diseases and C.
perfringens is clear and deﬁned, however the underlying
factors responsible for speciﬁc aspects of pathology
remains uncertain (Box 1, Box 2). Deciphering the genes
that are involved in the sporulation, germination, enzyme/
toxin production, oxygen tolerance, AMR and other novel
virulence factors could lead to more targeted clinical
preventions in C. perfringens-associated adult and neo-
natal intestinal diseases, whether it be humans or animals.
Important questions may be answered utilising WGS and
in silico tools, to delve into the genetic makeup of this
notorious, yet under-studied pathogen. In tandem further
in vitro and in vivo studies should be carried out to
conﬁrm the importance of suspected novel virulence
traits, i.e., to fulﬁl Molecular Koch’s postulates. These
approaches may help establish future platforms for dis-
ease prevention strategies such as vaccines, phage therapy,
microbiota-based therapeutics, or implementation of
speciﬁc antibiotic administration policies. Furthermore,
understanding the genomes will potentially enable epi-
demiological tracking (as is taking place for other patho-
genic bacteria), allowing us to pinpoint the origin and
route of spread of isolates in the hospital settings, which is
vital within clinical contexts.
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Box 2
What are the key knowledge gaps in understanding C. perfringens
as a pathogen, and what are the potential approaches to
investigate/mitigate the virulence of C. perfringens in clinical
diseases?
Questions
● Compared to other pathogens (e.g., C. difﬁcile), there is limited
WGS data for C. perfringens, what is the genomic diversity of
this important pathogen?
● Can we use WGS to ‘type’ C. perfringens isolates, and can WGS
be used in diagnostics (including AMR proﬁling), and to track
spread in outbreaks settings?
● C. perfringens causes diverse diseases in a wide host range, but
what are the microbial virulence factors responsible for
pathology, and is this host/strain speciﬁc?
● What are the host immune cells/signalling cascades involved in
C. perfringens-associated clearance and/or pathology?
● C. perfringens can reside as a ‘normal’ member of the gut
microbiota, what are the external factors that may lead to
overgrowth and disease?
● Can C. perfringens be directly linked to NEC pathogenesis?
● What are the therapeutic approaches that could be used to
prevent C. perfringens infection in multi-host species?
Approaches
● Isolate diverse strains from various environments, i.e., from both
case and control samples
● Perform comprehensive bioinformatics analyses to understand
evolution, e.g., SNP based phylogeny, and investigate variants
and spread clinical settings
● Carry out pan-GWAS/comparative genomics to identify/predict
speciﬁc virulence genes related to disease development.
● Develop/optimise clinical diagnostics from faecal samples via
e.g. ultra-long read real-time sequencing method such as
Oxford Nanopore
● Develop and characterise in vivo infection models for different
disease types (e.g., NEC and gastroenteritis)
● Pinpoint speciﬁc virulence genes involved in infection via
bacterial transcriptomics (RNAseq) and knock-out bacterial
strains, to fulﬁl molecular Koch’s postulates.
● Perform microbiota proﬁling (e.g., 16S rRNA metagenomics or
shotgun metagenomics) to investigate the impact of C.
perfringens to microbiota members, and the role of microbiome
in C. perfringens infections
● Understand host defence mechanisms using immunological
approaches, and knock out in vivo models
● Develop therapeutics for C. perfringens infections including
phage therapy, vaccines, microbiota treatment i.e., probiotics.
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